1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with ag 538 in 1 studies
Studies (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Trials (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Recent Studies (post-2010) (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Studies (ag 538) | Trials (ag 538) | Recent Studies (post-2010) (ag 538) |
---|---|---|---|---|---|
9 | 0 | 2 | 30 | 0 | 15 |
Protein | Taxonomy | 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50) | ag 538 (IC50) |
---|---|---|---|
integrase, partial | Human immunodeficiency virus 1 | 4.0628 | |
lens epithelium-derived growth factor p75 | Homo sapiens (human) | 4.0628 | |
alkaline phosphatase, intestinal | Homo sapiens (human) | 3.545 | |
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | 9.49 | |
intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | 3.6945 | |
alkaline phosphatase, germ cell type preproprotein | Homo sapiens (human) | 5.59 | |
Epidermal growth factor receptor | Homo sapiens (human) | 2.3603 | |
Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.061 | |
DNA-(apurinic or apyrimidinic site) endonuclease | Homo sapiens (human) | 0.28 | |
large T antigen | Betapolyomavirus macacae | 0.82 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and ag 538
Article | Year |
---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |